BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Special Report

All Special Reports
Datamonitor Healthcare Systemic Lupus Erythematosus KOL Interviews

Retail Price: $599.00

*BioMedTracker Subscriber Price: $399.00 - click here to log in
August 18, 2017
Datamonitor Healthcare interviewed two experts on systemic lupus erythematosus (SLE) based in the US to gauge their views on currently available treatment options, pipeline drugs and challenges with clinical trial design in SLE. The specific drugs discussed include anifrolumab [AZN], atacicept [MKGAY], Benlysta / belimumab [GSK], Benlysta SC [GSK], Lupuzor / rigerimod, Luveniq / voclosporin, Orencia / abatacept [BMY], Rituxan / rituximab [RHHBF] and Xeljanz/Xeljanz XR / tofacitinib [PFE]. The two interviews were combined into a single report.

If you are a KOL Insight Subscriber, please access the first and second interview from our KOL Insight portal (Subscribers only).

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.

For our disclosures, please read the Biomedtracker Research Standards.

Indications Covered: Systemic Lupus Erythematosus (SLE)